Skip to main content

Table 2 Final round 3 voting on ten rheumatoid arthritis–specific key performance indicators for centralized intake

From: Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis

  Median (range) and percentage of participants voting ≥7 on 1–9 scale for each domain (n = 23 unless otherwise specified)
  Scientific validity Face validity Feasibility: information availability Importance Likelihood of use
KPI 2: Time from RA referral receipt to referral completion for initially incomplete referrals 7 (5–8), 61 % 7 (6–8), 74 % 8 (6–8), n = 22 (64 %) 8 (7–8), 78 % 7 (6–8), 65 %
KPI 4: Percentage of RA referrals received with complete information 7 (7–8), 78 % 8 (7–8), 83 % 7 (6–8), n = 22 (59 %) 8 (7–8), n = 22 (82 %) 7 (6–8), n = 22 (68 %)
KPI 6: Waiting times for rheumatologist consultation for patients with new-onset rheumatoid arthritis N/Aa N/Aa 8 (8–9), n = 21 (95 %) 9 (8–9), n = 22 (100 %) 9 (9–9), n = 22 (100 %)
KPI 7: Time to disease-modifying antirheumatic drug therapy for patients with new-onset RA N/Aa N/Aa 7 (6–8), n = 22 (68 %) 9 (8–9), 91 % 9 (8–9), n = 22 (100 %)
KPI 8: Percentage of patients with new-onset RA with at least one visit to a rheumatologist in the first year of diagnosis N/Aa N/Aa 7 (6–8), n = 21 (57 %) 8 (7–9), 78 % 8 (7–8), 83 %
KPI 10: Rheumatologists per 100,000 population N/Aa N/Aa 7 (6–8), n = 21 (62 %) 7 (6–7), n = 22 (59 %) 7 (5–7), n = 21 (52 %)
KPI 17: Waiting times for patients with established RA 8 (8–9), 96 % 9 (8–9), 96 % 8 (7–8), n = 22 (77 %) 8 (8–9), 91 % 8 (8–9), 96 %
KPI 18: Percentage of rheumatoid arthritis patients treated with a disease-modifying antirheumatic drug during the measurement year N/Aa N/Aa 8 (6–9), 70 % 8 (8–9), 83 % 9 (8–9), 83 %
KPI 28: Ratio of patient flow to clinic capacity of RA teams participating in centralized intake 7 (6–8), n = 22 (73 %) 8 (7–8), n = 22 (82 %) 7 (5–8), n = 22 (55 %) 7 (7–8), 83 % 8 (7–9), n = 22 (86 %)
KPI 31: Agreement of centralized intake suspected diagnosis versus confirmed diagnosis of RA 8 (6–8), n = 21 (71 %) 8 (6–8), 74 % 7 (5–8), n = 22 (55 %) 8 (7–9), n = 22 (86 %) 8 (7–9), n = 21 (76 %)
  1. RA rheumatoid arthritis
  2. aKey performance indicators (KPIs) 6, 7, 8, 10 and 18 were harmonized with the Arthritis Alliance of Canada performance measure set for inflammatory arthritis which used a similar process for development and scientific validity and face validity were not examined again in the present study